INVESTORS
AND MEDIA

Transforming Lives Through Genetic Discovery

We seek to make a big difference in genetic disorders. At BioMarin, through our unparalleled expertise in genetics and molecular biology, we will continue to develop targeted therapies that address the root cause of the conditions we seek to treat. Applying our knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most.

>$2 Billion

in 2023 FY Total Revenues

80 Countries

Commercial Presence

World-class Capabilities

Manufacturing, R&D, Regulatory, and Commercial

"Core 5" Product Framework

Genetic, Targeted, Assessable, Transformational, Commercially Competitive

News

View All News

Events

View All Events

Q4

2024

Latest Quarterly Reports

Press Release

Presentation

Webcast
VIEW ALL FINANCIAL REPORTS
Commitment Image

A commitment to corporate responsibility.

We are committed to conducting our operations and managing our products in a responsible manner and in accordance with applicable laws, rules, and regulations. We regularly review our operations to improve efficiency and reduce environmental impact where appropriate.

Learn More

We take on the biggest challenges in rare disease.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

Learn More
Science Image

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Biomarin Pharmaceutical Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Biomarin Pharmaceutical Inc. to send you the requested Investor Email Alert updates.

* Required

Investor Alert Options
Unsubscribe